Home News DGAP-News: Biotest AG: Biotest shows sales growth in the first quarter of...

DGAP-News: Biotest AG: Biotest shows sales growth in the first quarter of 2010 despite a difficult environment

381
0

Release of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The content of the The issuer / publisher is solely responsible.
—————————————————————————
Biotest shows sales growth in the first quarter of 2010 despite difficult environment
– Q1 2010 by sales growth of 5.2%, EBIT decrease high
R & D expenses, as well as price pressure
– Net income tripled to 22.6 million EUR by
Capital gains Medical Diagnostics
– Forecast for 2010 confirmed
Dreieich, 11 May 2010 – Biotest has sales in the first quarter of 2010 by 5.2% to EUR 115 million increase over last year. The Earnings before interest and tax (EBIT) amounted to 12.3 million EUR, an Decrease of 18.0%
compared to the same period. The main reason which is significantly increased R & D expenditures, especially in Area of plasma proteins, as well as in the biotherapeutics. Addition to above, significant price declines in Immunoglobulins in some key European markets lower Profitability.
The result after taxes for the Biotest Group in the first quarter of 2010 is more than three times as high as in the prior year period. It rose from 7.5 Million EUR to 22.6 million EUR to. This includes EUR 15.1 million from the Sale of the business of Medical Diagnostics.
The Board confirms the Annual Report 2009 objectives set for the full year 2010. Biotest continues to expect Sales growth in the low single digit percentage range, and expects a operating profit (EBIT) at the level of 2009, provided that There are no further price declines and we manage our products increasingly price-sensitive markets in less to sell.
Detailed information on business development in the Segments as well as on progress in implementing the Corporate strategy includes the quarterly report. He is on the website of the Company (www.biotest.de) together with a brief presentation on today’s conference call available.
Disclaimer
This document contains forward-looking statements to overall economic development and to the business, earnings, financial and Asset situation of Biotest AG and its subsidiaries. These statements based on current plans, estimates, forecasts and expectations of the company and thus subject to risks and Uncertainties that may cause the actual significantly deviates from the expected development. The forward Statements only as of the date of publication Validity. Biotest does not intend the forward-looking statements and assumes no obligation to update.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic medicines as well as reagents and systems for the microbiological monitoring. With a value chain, from the preclinical and clinical development to global commercialization enough Biotest has been a priority in immunology and Hematology specialist. developed segment plasma proteins and Biotest markets immunoglobulins, clotting factors, and albumins based on Based on human blood plasma are produced and in diseases the immune system or haematopoietic system are used. In the Biotherapeutics segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and Blood cancer progressing. The products of the segment Microbiological Monitoring come mainly in the Hygiene control is used. Biotest Employs over 1900 staff worldwide. The preferred shares of Biotest AG are listed on the SDAX of the German Stock Exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, Dr. Monika Buttkereit, Telephone: +49 (0) 6103 801-4406, E-mail: investor_relations@biotest.de Fax: +49 (0) 6103 801-347 www.biotest.de
11.05.2010 09:00 Ad-hoc reports, financial news and Press releases transmitted by DGAP. Media Library under http://www.dgap-medientreff.de and http://www.dgap.de
—————————————————————————
Language: German company: Biotest AG
Landsteiner Straße 5
63303 Dreieich
Germany Phone: 0 61 03-8 01-0 Fax: 0 61 03-8 01-150 E-Mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522 720 Indices: SDAX stockmarkets: regulated dealing in Frankfurt (Prime Standard); free trade
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service